• Purity

  >90%, by SDS-PAGE with silver staining

• Endotoxin Level

  <0.10 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its binding ability in a functional ELISA. When Recombinant Human IL-17 RE Fc Chimera is immobilized at 0.25 μg/mL (100 μL/well), the concentration of Recombinant Human IL-17C (Catalog # ) that produces 50% of the optimal binding response is 1.5-7.5 ng/mL.

• Source

  Chinese Hamster Ovary cell line, CHO-derived

  Human IL-17 RE (Thr155-His454) Accession # Q8NFR9	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #

• N-terminal Sequence    
  Analysis

  Thr155

• Structure / Form

  Disulfide-linked homodimer

• Predicted Molecular Mass

  61 kDa (monomer)

• SDS-PAGE

  62-75 kDa, reducing conditions

Background: IL-17 RE

Interleukin-17 Receptor E (IL-17 RE) is an approximately 70 kDa (predicted) transmembrane protein in the family of IL-17 receptors. IL-17 RE is required for mediating the pro-inflammatory and homeostatic actions of IL-17C in the skin and mucosa (1, 2). Mature human IL-17 RE consists of a 431 amino acid (aa) extracellular domain, a 21 aa transmembrane segment, and a 192 aa cytoplasmic domain with one SEFIR/TIR domain (3). Within aa 115-454, human IL-17 RE shares 79% aa sequence identity with mouse and rat IL-17 RE. Alternative splicing of human IL-17 RE generates additional isoforms with a 116 aa N-terminal deletion and/or substitution and truncation in the ECD following aa 268 or aa 433. IL-17 RE is expressed on keratinocytes, mucosal epithelial cells, Th17 cells, and gamma /δ T cells (4, 5). It associates with the widely expressed IL-17 RA to form a heterodimeric receptor for IL-17C (4-6). IL-17C binds to IL-17 RE with high affinity and to IL-17 RA with low affinity (4, 5). IL-17C expression is induced by inflammatory stimulation in colon and airway epithelial cells, keratinocytes, CD4  ⁺ T cells, macrophages, and dendritic cells (4, 6, 7-9). It is up-regulated in various chronic inflammatory diseases including psoriasis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD) (7, 8, 10). IL-17 RE is reciprocally down-regulated in psoriatic lesions (10). The interaction of IL-17C with IL-17 RE promotes mucosal immunity through the induction of anti-bacterial peptides and pro-inflammatory cytokines and chemokines (4, 6, 8, 9). IL-17C action supports the integrity of the colon epithelium following infection induced damage (4, 6, 11) but also contributes to psoriatic skin thickening and the progression of arthritis (4, 8, 9). IL-17C is additionally up-regulated in Th17 cell dependent autoimmunity (5). In this setting, it exacerbates disease severity by inducing Th17 cell production of IL-17A, IL-17F, IL-22, CCR6, and CCL20 (5). The up-regulation of IL-17 RE in hepatocellular carcinoma is associated with poor prognosis (12).

• References:

1. Pappu, R. et al. (2012) Trends Immunol. 33:343.

2. Rubino, S.J. et al. (2012) Trends Immunol. 33:112.

3. Li, T.S. et al. (2006) Cell. Signal. 18:1287.

4. Ramirez-Carrozzi, V. et al. (2011) Nat. Immunol. 12:1159.

5. Chang, S.H. et al. (2011) Immunity 35:611.

6. Song, X. et al. (2011) Nat. Immunol. 12:1151.

7. Pfeifer, P. et al. (2013) Am. J. Respir. Cell Mol. Biol. 48:415.

8. Johnston, A. et al. (2013) J. Immunol. 190:2252.

9. Yamaguchi, Y. et al. (2007) J. Immunol. 179:7128.

10. Johansen, C. et al. (2009) Br. J. Dermatol. 160:319.

11. Reynolds, J.M. et al. (2012) J. Immunol. 189:4226.

12. Liao, R. et al. (2013) J. Exp. Clin. Cancer Res. 32:3.

• Long Name:

  Interleukin 17 Receptor E

• Entrez Gene IDs:

  132014 (Human); 57890 (Mouse); 362417 (Rat)

• Alternate Names:

  IL-17 RE; IL-17 receptor E; IL17RE; IL-17RE; Il25r; interleukin 17 receptor E